about
Lacosamide add-on therapy for partial epilepsyLacosamide monotherapy for epilepsyLacosamide add-on therapy for partial epilepsyLacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safetySynthesis and anticonvulsant activities of N-benzyl (2R)-2-acetamido-3-oxysubstituted propionamide derivativesIon channels as drug targets in central nervous system disordersTranslational investigation and treatment of neuropathic painLacosamide as a new treatment option in status epilepticusLacosamide: a new approach to target voltage-gated sodium currents in epileptic disordersVertebrate paralogous CRMPs in nervous system: evolutionary, structural, and functional interplay.Lacosamide in status epilepticus: Systematic review of current evidence.The safety of lacosamide for treatment of seizures and seizure prophylaxis in adult hospitalized patientsLacosamide for the prevention of partial onset seizures in epileptic adults.Prevention of posttraumatic axon sprouting by blocking collapsin response mediator protein 2-mediated neurite outgrowth and tubulin polymerization.Recent and future advances in the treatment of status epilepticusEslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action.Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.Opening Pandora's jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, and central disorders.Clinical perspectives on lacosamideTransitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions.Lacosamide for the treatment of diabetic neuropathic pain.Drug interactions involving the new second- and third-generation antiepileptic drugs.The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experienceLacosamide: new adjunctive treatment option for partial-onset seizures.Lacosamide and epilepsy.Pharmacological management of seizures and status epilepticus in critically ill patients.Novel medications for epilepsy.Review of therapeutic options for adjuvant treatment of focal seizures in epilepsy: focus on lacosamide.Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.Recent and future antiepileptic drugs and their impact on cognition: what can we expect?Lacosamide in patients with pharmacoresistant epilepsy.Neurological perspectives on voltage-gated sodium channels.Medical management of refractory epilepsy--practical treatment with novel antiepileptic drugs.Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats.The Safety and Effectiveness of Intravenous Lacosamide for Refractory Status Epilepticus in the Critically Ill.Effects of lacosamide "a novel antiepileptic drug" in the early stages of chicken embryo development.New treatment option for partial-onset seizures: efficacy and safety of lacosamide.The acute and chronic effects of the novel anticonvulsant lacosamide in an experimental model of status epilepticus.Status epilepticus developing during lacosamide monotherapy.Acute liver failure associated with levetiracetam and lacosamide combination treatment for unspecified epileptic disorder.
P2860
Q24187143-0F5F2733-0F04-4223-BAF2-062DB53D8423Q24187569-0DCEA5F7-14AF-4AC6-A082-760641F8E763Q24236785-71BE7ACD-7CA9-4D4F-A766-BC4C0E707983Q24644936-EA05406F-DFF6-436C-93C2-38BA4E0F9E76Q24657737-4CBE49FC-9FBD-4C5B-AE2D-B312302EC3A7Q27004533-28BB12B7-C135-49FE-AC35-2062AC740E6DQ27011346-6119EA6D-95C3-477B-B4B1-4BFEF2F35A55Q27014681-2BA711B1-37A1-4187-BE97-8AD1650091C8Q28833549-3693CFAB-B557-4893-A686-A2C995EAB68FQ30363247-C5AD5E4C-2E4A-4AF3-95BE-FA19A38EEBF0Q30399934-3DD16E8F-47CC-4168-A981-806B0A020025Q33410040-C6FC23CA-AC9A-4E88-A889-17924AE6A400Q34122954-D7494355-CC83-42D9-A8DB-2FB257FC0560Q34203586-3146C26C-B27B-4EEB-828F-F9839F197F35Q34409078-57FCA5F6-1A8C-4B7F-97CC-A4DCDDF0E9FEQ35664957-E06030E6-7F2E-46C0-8987-25F9FF3631E3Q35761335-70D67255-7E3C-43C7-A464-B79C77179FB0Q36517220-512E03D9-5D99-4778-8DEF-357DEE2B8C98Q37156322-895501DD-46A6-4361-8D63-189524D24F26Q37313452-006F6194-2DE1-4C33-BF2C-6D203052FEF6Q37318134-2E5C7E98-9535-4944-A8C8-412F746DC599Q37658910-9B9440A9-40D4-4923-98F8-287037513438Q37722778-CA4150DC-72E4-486D-945C-103B523B6DF6Q37756145-CCE34C3C-1B86-4AE9-8638-B43D3797B753Q37800507-A8C2D097-73C1-42D4-9201-AFD586CB4484Q37867301-AEABE7BC-A79E-4776-A7C1-0A5A20DB4868Q37950518-99323D00-6861-4735-BA5F-1704FE78CD49Q37964697-50CB19F4-0323-433D-BABD-099F56FCDA25Q37992162-8343EA6A-01A8-4829-8A6C-0B771A877A30Q38014887-B0162A01-6CF3-41CA-9654-DD5FA799026DQ38032922-6BC28D22-F856-4CD0-855B-44248517CC4AQ38042001-47172766-E84A-40DC-85FB-461242CBA666Q38176649-BCF28166-E914-4FEB-A3BB-88D75B61D509Q38466904-D41B509E-210C-43E6-82EC-C3E005818AF7Q39008925-E18B8945-4BC0-4E46-915A-1942592C11F7Q39544054-95638666-31CA-4ACC-A87A-50C887367066Q41176899-00B38155-F967-4771-9F1E-461ED5383973Q41824004-1CCC20F8-2728-4893-964E-7332AFFB9A3DQ41875012-76B769E7-3BAD-4939-A2DE-8E6CCD5FB737Q42207670-22259937-9EB3-4614-8F94-13BB079DC510
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Lacosamide.
@ast
Lacosamide.
@en
Lacosamide.
@nl
type
label
Lacosamide.
@ast
Lacosamide.
@en
Lacosamide.
@nl
prefLabel
Lacosamide.
@ast
Lacosamide.
@en
Lacosamide.
@nl
P2093
P2860
P1433
P1476
Lacosamide.
@en
P2093
Dirk Thomas
G David Rudd
Pamela Doty
Thomas Stoehr
P2860
P2888
P304
P356
10.1016/J.NURT.2006.10.002
P577
2007-01-01T00:00:00Z
P5875
P6179
1001033442